tiprankstipranks
Trending News
More News >
Restart Life Sciences (NMLSF)
OTHER OTC:NMLSF
Advertisement

Restart Life Sciences (NMLSF) Price & Analysis

Compare
30 Followers

NMLSF Stock Chart & Stats


NMLSF FAQ

What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was $0.02 and its highest was $0.10 in the past 12 months.
    What is Restart Life Sciences’s market cap?
    Restart Life Sciences’s market cap is $1.93M.
      When is Restart Life Sciences’s upcoming earnings report date?
      Restart Life Sciences’s upcoming earnings report date is Nov 26, 2025 which is in 88 days.
        How were Restart Life Sciences’s earnings last quarter?
        Restart Life Sciences released its earnings results on Aug 22, 2025. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.004.
          Is Restart Life Sciences overvalued?
          According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Restart Life Sciences pay dividends?
            Restart Life Sciences does not currently pay dividends.
            What is Restart Life Sciences’s EPS estimate?
            Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Restart Life Sciences have?
            Restart Life Sciences has 33,230,354 shares outstanding.
              What happened to Restart Life Sciences’s price movement after its last earnings report?
              Restart Life Sciences reported an EPS of -$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 16.667%.
                Which hedge fund is a major shareholder of Restart Life Sciences?
                Currently, no hedge funds are holding shares in NMLSF

                Company Description

                Restart Life Sciences

                Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.

                Restart Life Sciences (NMLSF) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Cybin
                Braxia Scientific
                Entheon Biomedical
                Doseology Sciences

                Ownership Overview

                20.47%79.53%
                20.47% Insiders
                ― Other Institutional Investors
                79.53% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis